Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.18	0.35	1.24
Cash & Cash Equivalents	0.18	0.35	1.24
Cash Growth	-	-72.18%	-
Other Current Assets	0.02	0.02	0.48
Total Current Assets	0.2	0.36	1.72
Total Assets	-	0.36	1.72
Accounts Payable	-	2.93	2.61
Current Debt	-	0.21	-
Other Current Liabilities	1.11	0	0
Total Current Liabilities	1.11	3.14	2.61
Long-Term Debt	-	7.41	6.47
Other Long-Term Liabilities	-	0.62	0.69
Total Long-Term Liabilities	-	8.03	7.16
Total Liabilities	-	11.17	9.77
Total Debt	2.69	7.62	6.47
Debt Growth	-	17.66%	-
Retained Earnings	-	-46.95	-42.82
Shareholders' Equity	-38.7	-45.91	-42.06
Net Cash / Debt	-2.51	-7.27	-5.23
Working Capital	-0.91	-2.78	-0.89

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).